Articles from Synchron

Synchron, a category-defining brain-computer interface (BCI) company, announced today a step forward in implantable BCI technology to drive the future of neurotechnology. Synchron’s BCI technology, in combination with the NVIDIA Holoscan platform, is poised to redefine the possibilities of real-time neural interaction and intelligent edge processing.
By Synchron · Via Business Wire · January 13, 2025

Synchron, a brain-computer interface company, and Team Gleason, a foundation dedicated to improving the lives of people living with Amyotrophic Lateral Sclerosis (ALS), today announced an expanded partnership focused on raising awareness of Synchron’s BCI Community. The collaboration highlights a shared commitment to empowering people living with paralysis and accelerating the development of innovative solutions.
By Synchron · Via Business Wire · January 6, 2025

Synchron, a brain-computer interface company, today announced positive results from the COMMAND study evaluating the safety and efficacy of the Synchron brain computer interface (BCI) device in six participants over a 12-month period.
By Synchron · Via Business Wire · September 30, 2024

Synchron, the brain-computer interface (BCI) company, today announced the first use of Amazon’s Alexa by one of the patients implanted with the Synchron brain computer interface.
By Synchron · Via Business Wire · September 16, 2024

Synchron, the brain-computer interface (BCI) company, today announced the presentation of its COMMAND study results at the 2024 Congress of Neurological Surgeons (CNS) Annual Meeting, held September 28 – October 2, 2024, in Houston, Texas.
By Synchron · Via Business Wire · September 9, 2024

Synchron, the brain-computer interface (BCI) company, today announced the world’s first-ever use of Apple Vision Pro, by one of the patients implanted with the Synchron brain computer interface.
By Synchron · Via Business Wire · July 30, 2024

Synchron, the brain-computer interface (BCI) company developing endovascular technology to restore functionality in individuals with motor impairment, today announced the integration of generative AI, powered by OpenAI, into its brain-computer interface (BCI) platform in a new chat feature.
By Synchron · Via Business Wire · July 11, 2024

Synchron, the brain-computer interface (BCI) company developing endovascular technology to restore functionality in patients with motor impairment, today announced the launch of a community-centered BCI registry to bring patients, carers and clinicians together to learn how BCI is being designed to provide benefit to people with limited mobility.
By Synchron · Via Business Wire · April 8, 2024

Mass General Brigham is establishing the Implantable Brain-Computer Interface Collaborative Community (iBCI-CC). This is the first Collaborative Community in the clinical neurosciences that has participation from the U.S. Food and Drug Administration (FDA).
By Synchron · Via Business Wire · March 11, 2024

Synchron, the brain-computer interface (BCI) company developing endovascular technology to restore functionality in patients with motor impairment, today announced the acquisition of an equity stake in ACQUANDAS, a leading technology provider specializing in state-of-the-art high-precision components for the healthcare industry and other industries.
By Synchron · Via Business Wire · February 1, 2024

Synchron, the endovascular brain-computer interface (BCI) company developing technology designed to restore functionality in patients with motor impairment, today announced the appointment of Riki Banerjee, Ph.D., to Chief Technology Officer (CTO). Banerjee will be responsible for leading all research and development (R&D) activities, including advancing Synchron’s neuroprosthesis device for patients with severe paralysis. Banerjee will succeed Nick Opie, Ph.D., the founding CTO and co-founder of Synchron who remains on the Board of Directors.
By Synchron · Via Business Wire · January 3, 2024

Synchron, the endovascular brain-computer interface (BCI) company developing technology designed to restore functionality in patients with motor impairment, today announced the appointment of Andy Rasdal to its Board of Directors. Mr. Rasdal brings more than 30 years of experience of developing and commercializing novel medical devices.
By Synchron · Via Business Wire · December 11, 2023

Synchron, the endovascular brain-computer interface (BCI) company developing technology to restore functionality in patients with severe paralysis, today announced completion of patient enrollment in the US-based COMMAND trial.
By Synchron · Via Business Wire · September 5, 2023

Synchron, the endovascular brain-computer interface (BCI) company developing technology to restore functionality in patients with severe paralysis, today announced the COMMAND trial is commencing at Gates Vascular Institute, a Kaleida Health facility in Buffalo, N.Y. and teaching affiliate of the Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo (UB).
By Synchron · Via Business Wire · March 20, 2023

Synchron, the endovascular brain-computer interface (BCI) company, announced today an oversubscribed $75 million Series C financing round led by ARCH Venture Partners. Gates Frontier, Bezos Expeditions, Reliance Digital Health Limited, Greenoaks, Alumni Ventures, Moore Strategic Ventures, and Project X join ARCH as new additional investors. Existing investors, including Khosla Ventures, NeuroTechnology Investors, METIS, Forepont Capital Partners, ID8 Investments, Shanda Group and University of Melbourne participated in the round. The Series C funding brings the total amount raised since inception to $145 million.
By Synchron · Via Business Wire · December 15, 2022

Synchron, an endovascular brain-computer (BCI) interface company, today announced the appointment of Kurt Haggstrom as Chief Commercial Officer. Haggstrom brings an extensive background in medical device commercialization and product launches, with a technical background in R&D engineering, holding over 20 U.S. patents.
By Synchron · Via Business Wire · July 13, 2022

Team Gleason and Synchron, an endovascular brain computer interface company, today announced a partnership agreement to provide patient-focused feedback on their platform to transform daily life for patients with physical and speech disabilities like ALS, muscular dystrophy, and cerebral palsy.
By Synchron · Via Business Wire · May 12, 2022

Synchron, a brain computer interface (BCI) company, today announced the results from a study in which four people with ALS received an implant of Synchron’s Stentrode™ device, a small mesh-like material inserted within a patient’s blood vessel that doesn’t require invasive open-brain surgery. The results were presented today as part of an exclusive press briefing highlighting breakthrough science at the American Academy of Neurology’s 74th Annual Meeting, held in Seattle, Washington (April 2-7) and virtually (April 24-26).
By Synchron · Via Business Wire · March 29, 2022